Biosect., quote:"For a Merck or BMY, they can likely handle themselves and even then they will have issues. For a tiny company like this one, it’s just tempting fate."
I couldn't agree with you more. In the last year and a half or so, BP's have introduced their blockbuster drugs in China through various Chinese Pharma partnerships. For now, BP's enjoy earning at least two times the annual revenue compared to US and EU sales. But as you say, BP's have deep pipelines and are obviously willing to gamble their bread and butter blockbusters, as they look to introduce new ones going forward. After all, with all these new AI Discovery companies popping up, new blockbuster treatments are likely to overtake the current ones by the time the Chinese launch their own copies.
ILT
News 
Market Data 
Discover 
